Why obesity drugs work better for some people: these genes hold clues

Key Points:

• Scientists have identified genetic variants that influence individual responses to obesity drugs, with some variants linked to greater weight loss from GLP-1 medications and others associated with increased side effects like nausea.
• The study analyzed data from nearly 28,000 users of the DNA-testing service 23andMe who reported taking weight-loss drugs, providing a large sample size for robust findings.
• Although the genetic effect on weight loss was relatively small—people with one copy of a specific gene variant lost about 0.76 kg more, and those with two copies lost about 1.5 kg more—the association with side effects was more pronounced.
• Researchers emphasize that genetics is only one of many factors influencing weight loss outcomes, and the findings are not yet ready for clinical application in personalized treatment plans.
• The study highlights the variability in response to next-generation obesity drugs like semaglutide, where weight loss can range from negligible to over 25%, underscoring the complexity of treatment efficacy.